226 related articles for article (PubMed ID: 25832688)
41. Toxicity and outcome of radiotherapy with concomitant and adjuvant temozolomide in elderly patients with glioblastoma: a retrospective study.
Saito K; Mukasa A; Narita Y; Tabei Y; Shinoura N; Shibui S; Saito N
Neurol Med Chir (Tokyo); 2014; 54(4):272-9. PubMed ID: 24257502
[TBL] [Abstract][Full Text] [Related]
42. Fractionated Radiation for Newly Diagnosed Supratentorial Glioblastoma Multiforme: In Regard to Brachman et al.
Brown M; Bernhard E; Mitchel J; Stone H
Int J Radiat Oncol Biol Phys; 2016 Jan; 94(1):210-211. PubMed ID: 26700716
[No Abstract] [Full Text] [Related]
43. The value of temozolomide in combination with radiotherapy during standard treatment for newly diagnosed glioblastoma.
Park CK; Lee SH; Kim TM; Choi SH; Park SH; Heo DS; Kim IH; Jung HW
J Neurooncol; 2013 Apr; 112(2):277-83. PubMed ID: 23377829
[TBL] [Abstract][Full Text] [Related]
44. Concurrent and adjuvant temozolomide-based chemoradiotherapy schedules for glioblastoma. Hypotheses based on two prospective phase II trials.
Balducci M; Fiorentino A; De Bonis P; Chiesa S; Mangiola A; Mattiucci GC; D'Agostino GR; Frascino V; Mantini G; Alitto AR; Colosimo C; Anile C; Valentini V
Strahlenther Onkol; 2013 Nov; 189(11):926-31. PubMed ID: 23974823
[TBL] [Abstract][Full Text] [Related]
45. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.
Lai A; Tran A; Nghiemphu PL; Pope WB; Solis OE; Selch M; Filka E; Yong WH; Mischel PS; Liau LM; Phuphanich S; Black K; Peak S; Green RM; Spier CE; Kolevska T; Polikoff J; Fehrenbacher L; Elashoff R; Cloughesy T
J Clin Oncol; 2011 Jan; 29(2):142-8. PubMed ID: 21135282
[TBL] [Abstract][Full Text] [Related]
46. Conditional probability of survival and post-progression survival in patients with glioblastoma in the temozolomide treatment era.
McNamara MG; Lwin Z; Jiang H; Chung C; Millar BA; Sahgal A; Laperriere N; Mason WP
J Neurooncol; 2014 Mar; 117(1):153-60. PubMed ID: 24469855
[TBL] [Abstract][Full Text] [Related]
47. A pilot study of hypofractionated radiation therapy with temozolomide for adults with glioblastoma multiforme.
Terasaki M; Eto T; Nakashima S; Okada Y; Ogo E; Sugita Y; Tokutomi T; Shigemori M
J Neurooncol; 2011 Apr; 102(2):247-53. PubMed ID: 20640480
[TBL] [Abstract][Full Text] [Related]
48. Phase 1/1b study of lonafarnib and temozolomide in patients with recurrent or temozolomide refractory glioblastoma.
Yust-Katz S; Liu D; Yuan Y; Liu V; Kang S; Groves M; Puduvalli V; Levin V; Conrad C; Colman H; Hsu S; Yung WK; Gilbert MR
Cancer; 2013 Aug; 119(15):2747-53. PubMed ID: 23633392
[TBL] [Abstract][Full Text] [Related]
49. Interim Results of a Phase II Study of Hypofractionated Radiotherapy with Concurrent Temozolomide Followed by Adjuvant Temozolomide in Patients over 70 Years Old with Newly Diagnosed Glioblastoma.
Yusuf M; Ugiliweneza B; Amsbaugh M; Boakye M; Williams B; Nelson M; Hattab EM; Woo S; Burton E
Oncology; 2018; 95(1):39-42. PubMed ID: 29694955
[TBL] [Abstract][Full Text] [Related]
50. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
51. Prognostic factors in glioblastoma patients managed with radiotherapy combined with temozolomide.
Peponi E; Tourkantonis I; Tasiou I; Pavlidis N; Pentheroudakis G; Tsekeris P
J BUON; 2014; 19(3):718-23. PubMed ID: 25261658
[TBL] [Abstract][Full Text] [Related]
52. Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years.
Ohno M; Miyakita Y; Takahashi M; Igaki H; Matsushita Y; Ichimura K; Narita Y
Radiat Oncol; 2019 Nov; 14(1):200. PubMed ID: 31718669
[TBL] [Abstract][Full Text] [Related]
53. A phase II study of concurrent temozolomide and cis-retinoic acid with radiation for adult patients with newly diagnosed supratentorial glioblastoma.
Butowski N; Prados MD; Lamborn KR; Larson DA; Sneed PK; Wara WM; Malec M; Rabbitt J; Page M; Chang SM
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1454-9. PubMed ID: 15817350
[TBL] [Abstract][Full Text] [Related]
54. First-in-Human Phase I Clinical Trial of Pharmacologic Ascorbate Combined with Radiation and Temozolomide for Newly Diagnosed Glioblastoma.
Allen BG; Bodeker KL; Smith MC; Monga V; Sandhu S; Hohl R; Carlisle T; Brown H; Hollenbeck N; Vollstedt S; Greenlee JD; Howard MA; Mapuskar KA; Seyedin SN; Caster JM; Jones KA; Cullen JJ; Berg D; Wagner BA; Buettner GR; TenNapel MJ; Smith BJ; Spitz DR; Buatti JM
Clin Cancer Res; 2019 Nov; 25(22):6590-6597. PubMed ID: 31427282
[TBL] [Abstract][Full Text] [Related]
55. Phase 1/2 Trial of 5-Fraction Stereotactic Radiosurgery With 5-mm Margins With Concurrent and Adjuvant Temozolomide in Newly Diagnosed Supratentorial Glioblastoma: Health-Related Quality of Life Results.
Pollom EL; Fujimoto D; Wynne J; Seiger K; Modlin LA; Jacobs LR; Azoulay M; von Eyben R; Tupper L; Gibbs IC; Hancock SL; Li G; Chang SD; Adler JR; Harsh GR; Harraher C; Nagpal S; Thomas RP; Recht LD; Choi CYH; Soltys SG
Int J Radiat Oncol Biol Phys; 2017 May; 98(1):123-130. PubMed ID: 28586949
[TBL] [Abstract][Full Text] [Related]
56. A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma.
Morganti AG; Balducci M; Salvati M; Esposito V; Romanelli P; Ferro M; Calista F; Digesù C; Macchia G; Ianiri M; Deodato F; Cilla S; Piermattei A; Valentini V; Cellini N; Cantore GP
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):92-7. PubMed ID: 19683876
[TBL] [Abstract][Full Text] [Related]
57. Radiation therapy dose escalation for glioblastoma multiforme in the era of temozolomide.
Badiyan SN; Markovina S; Simpson JR; Robinson CG; DeWees T; Tran DD; Linette G; Jalalizadeh R; Dacey R; Rich KM; Chicoine MR; Dowling JL; Leuthardt EC; Zipfel GJ; Kim AH; Huang J
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(4):877-85. PubMed ID: 25257812
[TBL] [Abstract][Full Text] [Related]
58. Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.
Grossman SA; Ye X; Piantadosi S; Desideri S; Nabors LB; Rosenfeld M; Fisher J;
Clin Cancer Res; 2010 Apr; 16(8):2443-9. PubMed ID: 20371685
[TBL] [Abstract][Full Text] [Related]
59. Phase I study of arsenic trioxide and temozolomide in combination with radiation therapy in patients with malignant gliomas.
Grimm SA; Marymont M; Chandler JP; Muro K; Newman SB; Levy RM; Jovanovic B; McCarthy K; Raizer JJ
J Neurooncol; 2012 Nov; 110(2):237-43. PubMed ID: 22875709
[TBL] [Abstract][Full Text] [Related]
60. Encouraging experience of concomitant Temozolomide with radiotherapy followed by adjuvant Temozolomide in newly diagnosed glioblastoma multiforme: single institution experience.
Jalali R; Basu A; Gupta T; Munshi A; Menon H; Sarin R; Goel A
Br J Neurosurg; 2007 Dec; 21(6):583-7. PubMed ID: 18071985
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
